Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-12-13FDA Approved: BUPROPION — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Bupropion submitted by Zydus Pharmaceuticals USA Inc.
-
FDA approval · 2022-12-06FDA Approved: WELLBUTRIN SR — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for Wellbutrin SR (bupropion hydrochloride) submitted by GlaxoSmithKline LLC.
-
FDA approval · 2022-12-06FDA Approved: VILAZODONE HYDROCHLORIDE — Original Application (Exelan Pharmaceuticals Inc.)
FDA approved Exelan Pharmaceuticals' original application for vilazodone hydrochloride, providing a generic version of vilazodone hydrochlor…
-
FDA approval · 2022-12-05FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA has approved Lupin Pharmaceuticals' supplemental application for sertraline hydrochloride, allowing the generic to be marketed as part o…
-
FDA approval · 2022-11-29FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for escitalopram oxalate (a generic version of Lexapro), enabling market entry…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2022-11-29Clinical Trial Update: Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes [Phase 4]
A Phase 4 trial of vortioxetine monotherapy for major depressive disorder in patients with type 2 diabetes was withdrawn.
-
CLINICAL_TRIALS trial_result · 2022-11-29Clinical Trial Update: Pharmacogenetics Informed Tricyclic Antidepressant Dosing (PITA) [Phase 4]
Phase 4 trial update for pharmacogenetics-informed dosing of tricyclic antidepressants in major depressive disorder.
-
FDA approval · 2022-11-29FDA Approved: ESCITALOPRAM — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for escitalopram from Macleods Pharmaceuticals Limited, enabling the marketing of their generic …
-
FDA approval · 2022-11-28FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Rising Pharma Holdings, Inc.)
The FDA approves the original application for venlafaxine hydrochloride tablets from Rising Pharma Holdings, Inc., making a generic version …
-
FDA approval · 2022-11-23FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA has approved a supplemental application for escitalopram oxalate from Rising Pharma Holdings, Inc.
-
CLINICAL_TRIALS trial_result · 2022-11-22Clinical Trial Update: Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients [Phase 4]
A Phase 4 trial evaluating a fixed-dose intervention to enhance survival in patients with serious mental illness, including schizophrenia an…
-
FDA approval · 2022-11-21FDA Approved: CITALOPRAM — Supplemental Application (Cipla USA Inc.)
The FDA approved a supplemental application for Cipla USA Inc. to market generic citalopram. This action confirms the availability of a gene…
-
FDA approval · 2022-11-21FDA Approved: VENLAFAXINE — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for venlafaxine submitted by Ascend Laboratories, LLC.
-
FDA approval · 2022-11-15FDA Approved: FLUOXETINE HYDROCHLORIDE — Original Application (Upsher-Smith Laboratories, LLC)
The FDA approved Upsher-Smith's fluoxetine hydrochloride as an original generic application, allowing the generic product to be marketed wit…
-
CLINICAL_TRIALS trial_result · 2022-11-10Clinical Trial Update: A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder [Phase 3]
Phase 3 trial evaluating SAGE-217 for treatment of adult major depressive disorder has completed; results posted in 2022.
-
FDA approval · 2022-11-09FDA Approved: TRAZODONE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for trazodone hydrochloride by Teva Pharmaceuticals USA, Inc., authorizing changes to the produc…
-
FDA approval · 2022-11-09FDA Approved: TRAZODONE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for trazodone hydrochloride from Teva Pharmaceuticals USA, Inc. under ANDA071524, approving a generi…
-
FDA approval · 2022-11-09FDA Approved: TRAZODONE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for trazodone hydrochloride submitted by Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2022-11-09FDA Approved: FLUOXETINE HYDROCHLORIDE — Original Application (ANI Pharmaceuticals, Inc.)
FDA approves ANI Pharmaceuticals' original application for fluoxetine hydrochloride, a generic version of fluoxetine.
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Study of Neural Responses Induced by Antidepressant Effects [Phase 2, Phase 3]
Phase 2/3 clinical trial investigating neural responses induced by antidepressant effects in major depressive disorder has completed with re…
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Reducing Health Risk Behavior and Improving Health in Adolescents With Depression [Phase 1, Phase 2]
A Phase 1/2 clinical trial aimed at reducing health risk behaviors and improving health in adolescents with depression has completed.
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: 7-day Simvastatin and Emotional Processing [Phase 1, Phase 2]
Clinical trial update for a 7-day simvastatin intervention in depression and inflammation, completed phases 1 and 2.
-
FDA approval · 2022-10-27FDA Approved: ARIPIPRAZOLE — Original Application (Advagen Pharma Ltd)
FDA approves Advagen Pharma Ltd's original application for a generic aripiprazole product.
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone [Phase 3]
Phase 3 trial evaluating cariprazine as an adjunct to antidepressant therapy in adults with major depressive disorder after inadequate respo…
-
FDA approval · 2022-10-25FDA Approved: ARIPIPRAZOLE — Original Application (Chartwell RX, LLC)
The FDA approved Chartwell RX, LLC's original application for a generic aripiprazole product. Aripiprazole is used to treat schizophrenia, b…